


# Breast Cancer Market to Grow at CAGR of 5.58% during 2024-2034

BROOKLYN, NY, USA, April 11, 2024  
/EINPresswire.com/ -- Market  
Overview:

The [breast cancer market](#) is expected to exhibit a CAGR of 5.58% during 2024-2034. The breast cancer market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as



treatment methods, drugs available in

the market, drugs in development, the market share of various therapies, and the market's performance in the seven major regions. Additionally, the report evaluates the performance of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in the report. This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone interested or involved in the breast cancer market.

Request for a Sample of this Report: <https://www.imarcgroup.com/breast-cancer-market/requestsampl>

## Breast Cancer Market Trends:

Breast cancer is a persistent ailment wherein atypical breast cells proliferate and culminate in tumor formation. 99% of cases occur in women, and approximately 0.5-1% of cases occur in men. This illness originates within the milk duct or milk-producing lobules of the breast. A breast lump or thickness, changes in the skin surrounding the areola, abnormal fluid discharge, changes in the look of the breast, and skin dimpling or redness can all be indications of this condition. Numerous tests, including blood tests, mammograms, breast ultrasounds, biopsies, and breast magnetic resonance imaging (MRI), are used to detect this condition. Breast cancer is treated using surgery, radiation therapy, and medications like chemotherapy, hormonal therapies, or targeted biological therapies.

Worldwide, the prevalence of breast cancer is increasing due to factors such as obesity, age, radiation exposure, family history, tobacco use, and postmenopausal hormone therapy. The World Health Organization reports that 67,000 women worldwide lost their lives to breast cancer, out of 2.3 million diagnoses. Also, 1 in 12 women receive a breast cancer diagnosis and 1 in 71 passes away from it in nations with extremely high Human Development Indexes (HDI). Apart from this, governments everywhere are proactively distributing information and raising awareness about breast cancer. The BreastScreen program, for example, was implemented in Australia and has resulted in a 21% decrease in the population's death rate from breast cancer.

Also, in recent years, the field of breast cancer has witnessed several breakthroughs in genetic testing, immunotherapy, and other areas. For example, tomosynthesis or three-dimensional (3D) mammography has been developed recently, which increases the detection rate by approximately 25% and lowers the number of false positives by approximately 15%. In addition, a number of organizations and pharmaceutical corporations are working together to intensify their efforts concerning breast cancer. For instance, M&S and Breast Cancer Now collaborated to generate £13 million in 2020, which has enabled the funding of 330,000 hours of top-notch research in the area.

#### Countries Covered:

United States

- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan

#### Analysis Covered Across Each Country:

Historical, current, and future epidemiology scenario

- Historical, current, and future performance of the breast cancer market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the breast cancer market
- Reimbursement scenario in the market
- In-market and pipeline drugs

This report also provides a detailed analysis of the current breast cancer marketed drugs and late-stage pipeline drugs.

#### In-Market Drugs:

## Drug Overview

- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance

## Late-Stage Pipeline Drugs:

### Drug overview

- Mechanism of action
- Regulatory status
- Clinical trial results
- Drug uptake and market performance

## Competitive Landscape With Key Players:

The competitive landscape of the breast cancer market has been studied in the report with the detailed profiles of the key players operating in the market.

## Key Players:

AstraZeneca Pharmaceuticals

Pfizer

Eli Lilly and Company

Novartis Pharmaceuticals

Genentech, Inc

Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: <https://www.imarcgroup.com/request?type=report&id=8353&flag=C>

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

## Browse Other Healthcare Reports:

<https://www.imarcgroup.com/amyloidosis-market>

<https://www.imarcgroup.com/lyme-disease-market>

<https://www.imarcgroup.com/charcot-marie-tooth-market>

<https://www.imarcgroup.com/recurrent-glioblastoma-market>

<https://www.imarcgroup.com/head-neck-cancer-market>

<https://www.imarcgroup.com/hernia-market>

<https://www.imarcgroup.com/seizures-market>

## About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Elena Anderson

IMARC Services Private Limited

+ +1 631-791-1145

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/702842286>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.